BMO Initiates Coverage On This Gene Editing Spearhead

  • BMO Capital initiated coverage of Intellia Therapeutics Inc NTLA with a Market Perform rating and a $54 target price. 
  • The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. 
  • But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc EDIT, and high patient compliance remains.
  • Related: Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer.
  • Although early data suggest that lead asset NTLA-2001 can have a competitive profile in ATTR, penetration will be challenged due to alternative approved/investigational treatments characterized by favorable outcomes and high patient adherence. 
  • BMO writes that IND approval for NTLA-2001 can drive ~10-15%+ upside in NTLA.
  • Price Action: NTLA shares are up 4.17% at $43.17 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetInitiationSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!